How do you decide between IL-4/IL-13 blockade (dupixent) versus IL-13 blockade only (Adbry) as treatments for Atopic Dermatitis?

First, disclosure that I work closely with all companies in the systemic atopic dermatitis space. The best data we have says that dupilumab is more effective at 16 weeks but that the drugs are equally effective at 32 weeks. The caveat is that there are no head-to-head trials, this is based on review...

Clinical trials demonstrate somewhat better efficacy of Dupixent over Adbry. I had hoped that eliminating IL-4 blockade would have lessened the incidence of conjunctivitis, but this does not appear to be the case. Dupixent remains the gold standard of AD therapy and is approved for infants 6 months ...

Can’t beat Dr. @Dr. First Last’ answer! Very thorough and exactly how I think about the differences between the two as well. One small addition is that for patient assistance in tough situations like uninsured or Medicare copay, the companies do differ in their thresholds so I have had success getti...